Terfenadine pharmacokinetics in breast milk in lactating women

B. Daniel Lucas, Caryn Y. Purdy, Sheila K. Scarim, Suzanne Benjamin, Steven R. Abel, Daniel E. Hilleman

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The excretion of terfenadine into breast milk has not been reported previously. Disposition of terfenadine was prospectively studied in four healthy lactating mothers (age, 33 ± 4 years). Subjects received 60 mg terfenadine every 12 hours over a period of 48 hours to achieve steady-state milk and plasma concentrations. Milk and plasma samples were collected at 1/2 , 1, 1 1/2 , 2, 3, 4, 6, 8, 12, 24, and 30 hours after the last dose. Terfenadine and its active metabolite milk and plasma concentrations were quantitated by HPLC. Terfenadine was not detected in milk or plasma. Mean ± SD active metabolite data for milk and plasma are as follows: C(max) (ng/ml), 41.0 ± 16.4 for milk, 309.0 ± 120.5 for plasma; t(max) (hours), 4.3 ± 2.4 for milk, 3.9 ± 3.0 for plasma; t( 1/2 )β (hours), 14.2 ± 5.4 for milk, 11.7 ± 6.4 for plasma; AUC(0-12) (ng · hr/ml) 320.4 ± 99.8 for milk, 1590.0 ± 300.4 for plasma. Metabolite milk/plasma(AUC(0-12)) ratios ranged from 0.12 to 0.28 (mean, 0.21 ± 0.07). Newborn dosage estimates based on the highest measured concentration of terfenadine metabolite in milk suggests the maximum level of newborn exposure would not exceed 0.45% of the recommended maternal weight-corrected dose. Estimated amounts consumed by the neonate after the mother is given the recommended dose of the drug are not likely to result in plasma levels producing untoward effects.

Original languageEnglish
Pages (from-to)398-402
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume57
Issue number4
StatePublished - 1995

Fingerprint

Terfenadine
Human Milk
Milk
Pharmacokinetics
Mothers
Newborn Infant
Area Under Curve

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Daniel Lucas, B., Purdy, C. Y., Scarim, S. K., Benjamin, S., Abel, S. R., & Hilleman, D. E. (1995). Terfenadine pharmacokinetics in breast milk in lactating women. Clinical Pharmacology and Therapeutics, 57(4), 398-402.

Terfenadine pharmacokinetics in breast milk in lactating women. / Daniel Lucas, B.; Purdy, Caryn Y.; Scarim, Sheila K.; Benjamin, Suzanne; Abel, Steven R.; Hilleman, Daniel E.

In: Clinical Pharmacology and Therapeutics, Vol. 57, No. 4, 1995, p. 398-402.

Research output: Contribution to journalArticle

Daniel Lucas, B, Purdy, CY, Scarim, SK, Benjamin, S, Abel, SR & Hilleman, DE 1995, 'Terfenadine pharmacokinetics in breast milk in lactating women', Clinical Pharmacology and Therapeutics, vol. 57, no. 4, pp. 398-402.
Daniel Lucas B, Purdy CY, Scarim SK, Benjamin S, Abel SR, Hilleman DE. Terfenadine pharmacokinetics in breast milk in lactating women. Clinical Pharmacology and Therapeutics. 1995;57(4):398-402.
Daniel Lucas, B. ; Purdy, Caryn Y. ; Scarim, Sheila K. ; Benjamin, Suzanne ; Abel, Steven R. ; Hilleman, Daniel E. / Terfenadine pharmacokinetics in breast milk in lactating women. In: Clinical Pharmacology and Therapeutics. 1995 ; Vol. 57, No. 4. pp. 398-402.
@article{368c04c5ad00405db4929e86f7344654,
title = "Terfenadine pharmacokinetics in breast milk in lactating women",
abstract = "The excretion of terfenadine into breast milk has not been reported previously. Disposition of terfenadine was prospectively studied in four healthy lactating mothers (age, 33 ± 4 years). Subjects received 60 mg terfenadine every 12 hours over a period of 48 hours to achieve steady-state milk and plasma concentrations. Milk and plasma samples were collected at 1/2 , 1, 1 1/2 , 2, 3, 4, 6, 8, 12, 24, and 30 hours after the last dose. Terfenadine and its active metabolite milk and plasma concentrations were quantitated by HPLC. Terfenadine was not detected in milk or plasma. Mean ± SD active metabolite data for milk and plasma are as follows: C(max) (ng/ml), 41.0 ± 16.4 for milk, 309.0 ± 120.5 for plasma; t(max) (hours), 4.3 ± 2.4 for milk, 3.9 ± 3.0 for plasma; t( 1/2 )β (hours), 14.2 ± 5.4 for milk, 11.7 ± 6.4 for plasma; AUC(0-12) (ng · hr/ml) 320.4 ± 99.8 for milk, 1590.0 ± 300.4 for plasma. Metabolite milk/plasma(AUC(0-12)) ratios ranged from 0.12 to 0.28 (mean, 0.21 ± 0.07). Newborn dosage estimates based on the highest measured concentration of terfenadine metabolite in milk suggests the maximum level of newborn exposure would not exceed 0.45{\%} of the recommended maternal weight-corrected dose. Estimated amounts consumed by the neonate after the mother is given the recommended dose of the drug are not likely to result in plasma levels producing untoward effects.",
author = "{Daniel Lucas}, B. and Purdy, {Caryn Y.} and Scarim, {Sheila K.} and Suzanne Benjamin and Abel, {Steven R.} and Hilleman, {Daniel E.}",
year = "1995",
language = "English",
volume = "57",
pages = "398--402",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Terfenadine pharmacokinetics in breast milk in lactating women

AU - Daniel Lucas, B.

AU - Purdy, Caryn Y.

AU - Scarim, Sheila K.

AU - Benjamin, Suzanne

AU - Abel, Steven R.

AU - Hilleman, Daniel E.

PY - 1995

Y1 - 1995

N2 - The excretion of terfenadine into breast milk has not been reported previously. Disposition of terfenadine was prospectively studied in four healthy lactating mothers (age, 33 ± 4 years). Subjects received 60 mg terfenadine every 12 hours over a period of 48 hours to achieve steady-state milk and plasma concentrations. Milk and plasma samples were collected at 1/2 , 1, 1 1/2 , 2, 3, 4, 6, 8, 12, 24, and 30 hours after the last dose. Terfenadine and its active metabolite milk and plasma concentrations were quantitated by HPLC. Terfenadine was not detected in milk or plasma. Mean ± SD active metabolite data for milk and plasma are as follows: C(max) (ng/ml), 41.0 ± 16.4 for milk, 309.0 ± 120.5 for plasma; t(max) (hours), 4.3 ± 2.4 for milk, 3.9 ± 3.0 for plasma; t( 1/2 )β (hours), 14.2 ± 5.4 for milk, 11.7 ± 6.4 for plasma; AUC(0-12) (ng · hr/ml) 320.4 ± 99.8 for milk, 1590.0 ± 300.4 for plasma. Metabolite milk/plasma(AUC(0-12)) ratios ranged from 0.12 to 0.28 (mean, 0.21 ± 0.07). Newborn dosage estimates based on the highest measured concentration of terfenadine metabolite in milk suggests the maximum level of newborn exposure would not exceed 0.45% of the recommended maternal weight-corrected dose. Estimated amounts consumed by the neonate after the mother is given the recommended dose of the drug are not likely to result in plasma levels producing untoward effects.

AB - The excretion of terfenadine into breast milk has not been reported previously. Disposition of terfenadine was prospectively studied in four healthy lactating mothers (age, 33 ± 4 years). Subjects received 60 mg terfenadine every 12 hours over a period of 48 hours to achieve steady-state milk and plasma concentrations. Milk and plasma samples were collected at 1/2 , 1, 1 1/2 , 2, 3, 4, 6, 8, 12, 24, and 30 hours after the last dose. Terfenadine and its active metabolite milk and plasma concentrations were quantitated by HPLC. Terfenadine was not detected in milk or plasma. Mean ± SD active metabolite data for milk and plasma are as follows: C(max) (ng/ml), 41.0 ± 16.4 for milk, 309.0 ± 120.5 for plasma; t(max) (hours), 4.3 ± 2.4 for milk, 3.9 ± 3.0 for plasma; t( 1/2 )β (hours), 14.2 ± 5.4 for milk, 11.7 ± 6.4 for plasma; AUC(0-12) (ng · hr/ml) 320.4 ± 99.8 for milk, 1590.0 ± 300.4 for plasma. Metabolite milk/plasma(AUC(0-12)) ratios ranged from 0.12 to 0.28 (mean, 0.21 ± 0.07). Newborn dosage estimates based on the highest measured concentration of terfenadine metabolite in milk suggests the maximum level of newborn exposure would not exceed 0.45% of the recommended maternal weight-corrected dose. Estimated amounts consumed by the neonate after the mother is given the recommended dose of the drug are not likely to result in plasma levels producing untoward effects.

UR - http://www.scopus.com/inward/record.url?scp=0028940617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028940617&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 398

EP - 402

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -